These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 11137710)
1. Characterization of multidrug transporters in a normal renal tubular cell line resistant to doxorubicin. Multidrug transporters in the LLC-PK(1) cell line and its resistant counterpart. Decorti G; Rosati A; Candussio L; Giraldi T; Bartoli Klugmann F Biochem Pharmacol; 2001 Jan; 61(1):61-6. PubMed ID: 11137710 [TBL] [Abstract][Full Text] [Related]
2. Cytofluorimetric analysis of a renal tubular cell line and its resistant counterpart. Rosati A; Decorti G; Klugmann FB; Candussio L; Granzotto M; Melato M; Giraldi T Anticancer Res; 2000; 20(5B):3403-10. PubMed ID: 11131640 [TBL] [Abstract][Full Text] [Related]
3. Kinetics of doxorubicin handling in the LLC-PK1 kidney epithelial cell line is mediated by both vesicle formation and P-glycoprotein drug transport. Crivellato E; Candussio L; Rosati AM; Decorti G; Klugmann FB; Mallardi F Histochem J; 1999 Oct; 31(10):635-43. PubMed ID: 10576412 [TBL] [Abstract][Full Text] [Related]
4. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. van der Sandt IC; Blom-Roosemalen MC; de Boer AG; Breimer DD Eur J Pharm Sci; 2000 Sep; 11(3):207-14. PubMed ID: 11042226 [TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein in HK-2 proximal tubule cell line. Tramonti G; Romiti N; Norpoth M; Chieli E Ren Fail; 2001; 23(3-4):331-7. PubMed ID: 11499549 [TBL] [Abstract][Full Text] [Related]
6. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Anuchapreeda S; Leechanachai P; Smith MM; Ambudkar SV; Limtrakul PN Biochem Pharmacol; 2002 Aug; 64(4):573-82. PubMed ID: 12167476 [TBL] [Abstract][Full Text] [Related]
7. Modulation of multidrug resistant in cancer cells by EGCG, tannic acid and curcumin. Li H; Krstin S; Wink M Phytomedicine; 2018 Nov; 50():213-222. PubMed ID: 30466981 [TBL] [Abstract][Full Text] [Related]
8. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202 [TBL] [Abstract][Full Text] [Related]
9. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity. David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791 [TBL] [Abstract][Full Text] [Related]
10. Up-regulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment. Fardel O; Lecureur V; Daval S; Corlu A; Guillouzo A Eur J Biochem; 1997 May; 246(1):186-92. PubMed ID: 9210482 [TBL] [Abstract][Full Text] [Related]
11. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. Stein U; Walther W; Shoemaker RH J Natl Cancer Inst; 1996 Oct; 88(19):1383-92. PubMed ID: 8827016 [TBL] [Abstract][Full Text] [Related]
12. S9788 modulation of P-glycoprotein- and Multidrug-related protein-mediated multidrug resistance by Servier 9788 in doxorubicin-resistant MCF7 cells. Bichat F; Solis-Recendez G; Poullain MG; Poupon MF; Khayat D; Bastian G Biochem Pharmacol; 1998 Aug; 56(4):497-502. PubMed ID: 9763226 [TBL] [Abstract][Full Text] [Related]
13. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery. Gu J; Fang X; Hao J; Sha X Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500 [TBL] [Abstract][Full Text] [Related]
14. Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells. Liu F; Liu S; He S; Xie Z; Zu X; Jiang Y Oncol Rep; 2010 May; 23(5):1469-75. PubMed ID: 20372866 [TBL] [Abstract][Full Text] [Related]
15. Co-ordinate loss of protein kinase C and multidrug resistance gene expression in revertant MCF-7/Adr breast carcinoma cells. Budworth J; Gant TW; Gescher A Br J Cancer; 1997; 75(9):1330-5. PubMed ID: 9155054 [TBL] [Abstract][Full Text] [Related]
16. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Hasegawa S; Abe T; Naito S; Kotoh S; Kumazawa J; Hipfner DR; Deeley RG; Cole SP; Kuwano M Br J Cancer; 1995 May; 71(5):907-13. PubMed ID: 7734314 [TBL] [Abstract][Full Text] [Related]
17. Lack of elevated drug efflux in adriamycin-resistant immunoblastic B lymphoma cells with mdr1 overexpression. Chao CC FEBS Lett; 1995 Oct; 373(3):285-90. PubMed ID: 7589484 [TBL] [Abstract][Full Text] [Related]
18. Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells. Eijdems EW; Zaman GJ; de Haas M; Versantvoort CH; Flens MJ; Scheper RJ; Kamst E; Borst P; Baas F Br J Cancer; 1995 Aug; 72(2):298-306. PubMed ID: 7640209 [TBL] [Abstract][Full Text] [Related]
19. Activation of silent MDR1 genes in revertant cells by fusion with multidrug-resistant cells. Yusa K; Tamura J; Waki A; Tsuruo T Biochim Biophys Acta; 1995 Nov; 1269(3):260-6. PubMed ID: 7495879 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of P-glycoprotein in heat- and/or drug-resistant hepatoma variants. Pirity M; Hevér-Szabó A; Venetianer A Cytotechnology; 1996; 19(3):207-14. PubMed ID: 8862008 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]